[PREVIEW] A Saturday morning that changed everything...

Épisode de Pharma Minds par Nathalie Lahitte · 7 décembre 2025 · 4 min

In this preview, Marc de Garidel, CEO of Abivax, shares the moment a phase 3 trial delivered results far beyond expectations — a rare scientific milestone that triggered an intense 48-hour sprint and a record-breaking stock surge.

🎧 The full episode drops tomorrow on Pharma minds.

What you will learn in the full episode of tomorrow:

◾️ How Marc stepped into a company with almost no long-term plan… and why that turned out to be a surprising advantage.

◾️ The four pillars of a new strategy — and how one of them quietly set the stage for the breakthrough to come.

◾️ What it really takes to run a global phase 3 across dozens of countries — and why Abivax had to reinvent itself to pull it off.

◾️ A mechanism of action unlike anything else in IBD — and why this difference matters more than most people think.

◾️ The hidden lessons from a noisy phase 2 that helped transform the phase 3 into something no one saw coming.

◾️ A leadership philosophy built on transparency and speed, born from a single principle: in biotech, every day counts.

◾️ The unexpected market reaction that changed the fate of the company overnight — with numbers that almost don’t seem real.

A clear, concrete, and inspiring episode that sheds light on how Europe can regain its leadership in healthcare innovation.

See you tomorrow!

---

🎧 New here? To get a quick overview of the episodes, download “25 Tips for Purposeful Leadership”, a guide inspired by the best advice shared by my guests.

🤝 Want to connect or talk about your current challenges? Let’s connect on LinkedIn.

📩 Curious to dive deeper into the major shifts in the pharma and healthcare ecosystem? Subscribe to the Pharma Minds newsletter.

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Autres épisodes de « Pharma Minds »

• #53 - Libérer du temps soignant : le pari d'un ingénieur à la Clinique Pasteur 19 octobre 2026
• [EXTRAIT] « On a toujours fait comme ça » : comment faire accepter le changement ? avec Loïc Lagarde 18 octobre 2026
• "Europe's Access Dilemma" (BONUS) - The Innovation Wave? Europe’s Payers Aren’t Convinced 12 octobre 2026
• "Europe's Access Dilemma" (5/5) - "Germany has a target on its back" What will Europe give up? 5 octobre 2026
• "Europe's Access Dilemma" (4/5) - Pharma Innovation: Your 8-Year Competitive Window Is Now Just 3 28 septembre 2026
• "Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare. 21 septembre 2026
• "Europe's Access Dilemma" (2/5) - Europe Can't Pay More For Innovation: The Case For Co-developing With Asia 14 septembre 2026
• "Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why. 7 septembre 2026
• [Insights] Produits frontières : transformer la réglementation en avantage stratégique 2 septembre 2026
• "Executing differently takes courage" (5/5) - From managing global subsidiaries to walking the talk : when execution becomes personal 17 août 2026
• "Executing differently takes courage" (4/5) - Biotech survival and resource allocation : why execution is about choosing what not to do 10 août 2026
• "Executing differently takes courage" (3/5) - Trusting the ground : navigating volatility, growth and partnerships across the EEMEA zone 3 août 2026
• "Executing differently takes courage" (2/5) - The Chinese pharma ecosystem : balancing systemic scale and constant reinvention 27 juillet 2026
• "Executing differently takes courage" (1/5) Transforming Vidal : how a 20-year vision turned a paper book into digital infrastructure 20 juillet 2026
• [Insights] Groupements de pharmacies : ce qu’il faut retenir du rapport IGF-IGAS, avec Hugues Villey Desmeserets 8 juillet 2026

Tous les épisodes de Pharma Minds · Plus de podcasts Business